Revance Launches the Teoxane RHA® Collection with Mepivacaine
RVNCThe innovative filler line challenges the status quo by replacing the local anesthetic with mepivacaine. NASHVILLE, Tenn., Aug. 27, 2025 /PRNewswire/ -- Revance, a fast-growing global aesthetics and skincare company, announces the latest innovation in its aesthetic portfolio with the...
Crown Laboratories, a Revance Company, Ranks No. 3,991 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
RVNCWith Three-Year Revenue Growth of 91%, this Marks the Company's 12th Appearance on the List NASHVILLE, Tenn., Aug. 12, 2025 /PRNewswire/ -- Crown Laboratories, Inc., a Revance company, is proud to announce that it has ranked 3,991 on the annual Inc. 5000 list, the most prestigious ranking...
Crown Laboratories Extension Of Tender Offer To Acquire Revance Therapeutics, Inc. At A Price Of $3.10 Per Share In Cash
RVNCBarclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3
RVNCRevance Therapeutics Priced Upsized 8M Sharw Public Offering of Common Stock @$25/Share
RVNCRevance Announces Proposed Public Offering Of $150M Of Its Common Stock
RVNCWith New Growth Avenues, Analysts Boost Price Targets For This Botox Competitor
RVNCAnalyst Ratings for Revance Therapeutics
RVNCRevance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Needham Maintains Buy Rating for Revance Therapeutics: Here's What You Need To Know
RVNCNeedham has decided to maintain its Buy rating of Revance Therapeutics (NASDAQ:RVNC) and raise its price target from $25.00 to $35.00.
Shares of Revance Therapeutics are trading up 9.72% over the last 24 hours, at $27.76 per share.
What 5 Analyst Ratings Have To Say About Revance Therapeutics
RVNCRevance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
5 Analysts Have This to Say About Revance Therapeutics
RVNCWithin the last quarter, Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings:
Mizuho Maintains Buy on Revance Therapeutics, Raises Price Target to $30
RVNCBarclays Maintains Overweight on Revance Therapeutics, Raises Price Target to $35
RVNCHC Wainwright & Co. Maintains Buy on Revance Therapeutics, Raises Price Target to $29
RVNCNeedham Maintains Buy on Revance Therapeutics, Raises Price Target to $35
RVNCNeedham Gives Revance Therapeutics Buy Rating With Note Titled: FDA Approves Daxxify With Anticipated Product Label Differentiation; Raises Price Target From $25 To $35
RVNCRevance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines
RVNCThe United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ: RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severecfrown lines (glabellar lines) in adults.
Revance Announces FDA Approval of DAXXIFY For Injection, A Peptide-Formulated Neuromodulator With Long-Lasting Results
RVNC